The Lab Rats
The group is developing novel immunotherapies using the Adeno-associated virus (AAV) gene-therapy platform that are capable of not only preventing development of disease, but can also stop preexisting (reverse) disease in mouse models of Multiple Sclerosis.
PRINCIPAL INVESTIGATOR
Brad Hoffman
Dr. Hoffman is an Associate Professor and cellular immunologist with a major interest in immune modulation and tolerance induction using adeno-associated virus (AAV) gene therapy. Dr. Hoffman earned his Ph.D. in Immunology from Temple University School of Medicine in 2006. He subsequently performed postdoctoral research in gene therapy at University of Florida.
